Committed to defeating neurogenerative disease, Denali Therapeutics has exercised an option to acquire F-Star Gamma for US$24 M as well as potential milestone payments of up to US$447 M. F-Star has developed bispecific antibodies which can be utilised to carry drugs across the blood-brain barrier.